NUR 440 Module 1 Short Paper example

Does a Cold Spray Take the Sting Out? Appraising a Randomized Trial of Vapocoolant Spray Before Intravenous Cannulation

[Student Name]

Southern New Hampshire University

NUR 440: Research and Evidence-Based Practice

Module One Short Paper

[Instructor Name]

[Date]

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

Does a Cold Spray Take the Sting Out? Appraising a Randomized Trial of Vapocoolant Spray Before Intravenous Cannulation

The Practice Question

Nurses in the composite emergency department where this question arose start dozens of intravenous lines each shift. Patients often ask whether anything can make the needle hurt less, and the department stocks a vapocoolant spray, a fast-evaporating liquid that chills the skin for a few seconds, but few nurses use it and no one could say whether it works. The practice question was simple: in adults having a peripheral intravenous catheter placed, does vapocoolant spray reduce the pain of insertion compared with no spray or a placebo spray?

A search of the literature found a randomized controlled trial that addressed this question directly (Mace, 2017). The trial compared a vapocoolant spray with a placebo spray in adults undergoing intravenous cannulation, with neither patients nor the nurses placing the catheter knowing which spray was used. This paper appraises that trial and then places it beside a systematic review of vapocoolants (Hogan et al., 2014).

Design and Sampling

The study was a prospective, double-blind, randomized, placebo-controlled trial, the design best suited to testing whether an intervention causes an effect. Randomization means that each participant had an equal chance of receiving the active or the placebo spray, which should balance known and unknown factors, such as fear of needles or vein difficulty, between the groups. Adults undergoing intravenous cannulation in an emergency setting were enrolled, which matches the population of the practice question closely.

Two questions about sampling matter for applying the results. First, who was excluded? Trials often exclude patients who are critically ill, unable to rate pain or in need of immediate access, which means the results apply best to stable patients. Second, how large was the sample? A trial must enroll enough participants to detect a meaningful difference, so the reader should look for a sample size calculation planned before enrollment began; without one, a negative result could simply reflect too few participants, and a positive one could be less stable than it appears.

Controlling Bias

Pain is subjective, so expectations can change how much pain a person reports. The trial controlled this with a placebo spray that looked and felt similar to the active spray, and with blinding of both participants and staff. Without a placebo and blinding, patients who knew they had received the active spray might report less pain simply because they expected to, and nurses might unconsciously insert the catheter differently. Blinding also protects the measurement of the outcome, since the person recording pain scores did not know the group assignment.

One limit is that the cold sensation of a vapocoolant can be hard to disguise completely. If some participants guessed which spray they had, blinding would be partly compromised. A strong report would describe whether blinding was checked, and readers should look for that detail.

Outcome Measurement and Results

The main outcome was the patient's rating of pain from the cannulation on a standardized scale immediately after insertion. The trial found that pain scores were lower with the vapocoolant spray than with the placebo, a difference that was statistically significant, and adverse effects were minor and short-lived (Mace, 2017).

Statistical significance does not settle whether the difference matters to patients. The question to ask is how large the reduction was compared with the smallest change patients notice, often around one to two points on a zero-to-ten scale. A reduction of that size or larger would be clinically meaningful for a procedure performed many times a day, especially because the spray is quick, inexpensive and low in risk.

Summary of the Appraisal

The table below summarizes the trial's strengths and limitations.

Table 1

Appraisal of the Vapocoolant Trial

Ethical Considerations

Appraisal also asks whether a study was conducted ethically. A placebo-controlled trial of a comfort measure is reasonable only when the placebo group receives usual care, so that no one is denied a treatment already known to work. In this trial, participants in both groups received standard cannulation, and the only difference was the spray. Readers should also confirm that the study received review from an institutional review board and that participants gave informed consent before enrollment, which is especially important in emergency settings where patients may be anxious or in pain when asked to take part.

Placing the Trial in the Wider Evidence

A single trial is one piece of evidence. A systematic review of vapocoolants for venipuncture and intravenous cannulation found that in adults, vapocoolants reduced pain modestly compared with placebo or no treatment, while the evidence in children did not show a clear benefit (Hogan et al., 2014). The adult trial appraised here is consistent with the review's adult findings. Under common evidence hierarchies, a systematic review of randomized trials ranks above a single trial, and agreement between the two strengthens confidence in the result (Melnyk & Fineout-Overholt, 2023).

The practice judgment for the department is therefore cautious but positive: offering vapocoolant spray to adults before intravenous insertion is supported by evidence, inexpensive and low in risk, and patients can decline it. The evidence does not support the same recommendation for children, where other approaches may work better. The unit could measure patient-reported pain for a month before and after encouraging routine use to see whether the benefit appears in its own patients.

Conclusion

Appraising one trial step by step shows why its design, a double-blind randomized comparison with a placebo, makes its finding credible, and why questions about blinding, sampling and the size of the effect still matter. Placed beside a systematic review, the trial supports offering vapocoolant spray to adults before intravenous cannulation. The same process can be applied to any article a nurse brings to a unit's practice discussion.

References

Hogan, M.-E., Smart, S., Shah, V., & Taddio, A. (2014). A systematic review of vapocoolants for reducing pain from venipuncture and venous cannulation in children and adults. The Journal of Emergency Medicine, 47(6), 736-749. https://doi.org/10.1016/j.jemermed.2014.06.028

Mace, S. E. (2017). Prospective, double blind, randomized, controlled trial comparing vapocoolant spray versus placebo spray in adults undergoing intravenous cannulation. Scandinavian Journal of Pain, 17(1), 8-15. https://doi.org/10.1016/j.sjpain.2017.06.002

Melnyk, B. M., & Fineout-Overholt, E. (2023). Evidence-based practice in nursing and healthcare: A guide to best practice (5th ed.). Wolters Kluwer.